REG - Synairgen plc - Martin Murphy appointed as Non-Executive Director

SynairgenAnnouncement

16/01/2025 15:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250116:nRSP6574Ta&default-theme=true

RNS Number : 6574T  Synairgen plc  16 January 2025

 

Synairgen plc

('Synairgen' or the 'Company')

Martin Murphy appointed as Non-Executive Director

 

Southampton, UK - 16 January 2025: Synairgen plc (LSE: SNG), the respiratory
company developing SNG001, an investigational formulation for inhalation
containing the broad-spectrum antiviral protein interferon beta, today
announces the appointment of Martin Murphy to the Board as an independent
Non-Executive Director and Chair of the Remuneration Committee, effective
immediately.

Martin Murphy is a seasoned healthcare veteran with over 25 years of
leadership experience in life sciences investment. Previously, Martin Murphy
was co-founder of Syncona Limited, a FTSE 250 healthcare investment company,
and CEO and Investment Committee Chair of Syncona Investment Management
Limited. He now holds various Chair positions and is a Director and founding
investor of NASDAQ-listed Autolus Therapeutics plc. Between 2005-2012, he
served as a Managing Director of MVM Life Science Partners LLP. Martin holds a
PhD from the University of Cambridge and an MA in Biochemistry from the
University of Oxford.

Mark Parry-Billings, Chairman of the Board of Synairgen, added: "I'm pleased
to welcome Martin Murphy to our Board at Synairgen, where his proven track
record in guiding innovative healthcare companies will strengthen our
strategic direction. Martin's extensive experience in life sciences leadership
will prove invaluable as we prepare to begin our large Phase 2 INVENT trial in
the coming months."

Martin Murphy, Non-Executive Director of the Board of Synairgen, commented: "I
am delighted to be joining Synairgen's Board at this pivotal stage as the
Company plans to progress its INVENT trial investigating SNG001 in
mechanically ventilated patients. I look forward to collaborating with the
team and supporting the advancement of this potentially transformative
treatment for a patient group in critical need."

The following information regarding the appointment of Martin Murphy, aged 56,
is disclosed under Schedule 2(g) of the AIM Rules for Companies:

 

 

 

 Full name:                                                        Martin Patrick Murphy
 Age:                                                              56
 Shares held in the Company:                                       None
 Current directorships and/or partnerships:                        Former directorships and/or partnerships (within the last five years):
 Autolus Therapeutics PLC (formerly Autolus Therapeutics Limited)  Achilles Therapeutics UK Limited
                                                                   Anaveon AG
                                                                   Azeria Therapeutics Limited
                                                                   Clade Therapeutics, Inc.
                                                                   Neogene Therapeutics, Inc.
                                                                   Quell Therapeutics Limited
                                                                   Resolution Therapeutics Limited
                                                                   Syncona Development Limited
                                                                   Syncona Discovery Limited
                                                                   Syncona Investment Management Limited
                                                                   Syncona IP Holdco (2) Limited
                                                                   Syncona IP Holdco Limited

 

There are no further disclosures to be made under Schedule 2(g) of the AIM
Rules for Companies.

 

For further enquiries, please contact:

 Synairgen plc                                                      + 44 (0)23 8051 2800
 Media@synairgen.com (mailto:Media@synairgen.com)
 Cavendish Capital Markets Limited -                                + 44 (0)20 7220 0500

Nominated Adviser, joint broker and sole bookrunner
 Geoff Nash/Camilla Hume/Trisyia Jamaludin

 Deutsche Numis (Joint Broker)                                      + 44 (0) 20 7260 1000

 Freddie Barnfield, Duncan Monteith, Euan Brown

 ICR Healthcare (Financial Media and Investor Relations)            + 44 (0)20 3709 5700
 Mary-Jane Elliott/Namrata Taak/Lucy Featherstone
 synairgen@icrhealthcare.com (mailto:synairgen@icrhealthcare.com)

 

Notes for Editors

About Synairgen

Synairgen is a UK-based respiratory company focused on drug discovery and the
development of SNG001 (inhaled interferon beta) as potentially the first
host-targeted, broad-spectrum antiviral treatment delivered directly into the
lungs for severe viral lung infections.

Millions of people globally are hospitalised every year due to viral lung
infections and there are currently no approved antiviral therapies for the
majority of these patients. Synairgen is developing SNG001 to address this
need.

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen,
please see www.synairgen.com (http://www.synairgen.com)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAPKABNPBKDFDD